A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis

NCT02963506 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

303

Enrollment

INDUSTRY

Sponsor class

Conditions

Ankylosing Spondylitis

Interventions

OTHER: Placebo
DRUG: Bimekizumab

Sponsor

UCB Biopharma S.P.R.L.